Myths vs facts: Pharmakogenetik Medicheck and Darmgesundheit

Combining pharmacogenetic testing (e.g., Medicheck) with gut health analysis in a single product sounds appealing but lacks solid scientific backing. Pharmacogenetics has moderate evidence for certain drug-gene interactions (e.g., CYP2D6/CYP2C19 for antidepressants, VKORC1 for warfarin), but effect sizes are small and not deterministic. Gut health DNA tests, such as those based on FUT2 (rs1047781), provide only weak clues about microbiome composition; diet, environment, and lifestyle have far greater influence. Claims that a single DNA test can predict both drug response and gut flora comprehensively are not supported by robust studies. Many vendors mix validated pharmacogenetic markers with speculative microbiome SNPs to create a 'one-size-fits-all' package. Consumers should recognize that such combo tests are often marketing-driven and do not replace personalized medical advice. A more evidence-based approach is to limit pharmacogenetic testing to specific medications and assess gut health through dietary logs or stool microbiome analysis (e.g., 16S rRNA sequencing).